. Author manuscript; available in PMC: 2022 Jan 6.

Published in final edited form as: Acta Biomater. 2020 Aug 7;115:127–135. doi: 10.1016/j.actbio.2020.07.051

Table 2.

Characteristics of Responders and Non-responders to Mesh Removal.

	Responders (n = 9)	Non-responders (n = 8)	P value

Age (y)	57 (52.5–65.0)	55.5 (48.8–68.0)	0.82
BMI (kg/m²)	28.2 (26.2–31.6)	29.6 (23.5–32.4)	0.96
Duration implantation (months)	22.0 (10.5–61.3)	55.5(35.0–58.9)	0.17
Baseline VAS Pelvic Pain	45.0 (33–76)	45.5(16–84.5)	0.53
Fibrosis level (intensity)	54.6 (38.5–72.1)	66.2 (35.8–82.2)	0.89
Treg concentration (cells/mm²)	7.8 (1.3–10.2)	0.3 (0.5–3.4)	0.036
CD8 (cells/sample)	562.0 (289.5–829.0)	291.0 (100.8–544.8)	0.17
Treg/CD8 ratio (Treg /100 CD8)	2.7 (1.1–7.3)	1.1 (0.1–1.8)	0.07
TGF-β1 (pg/μg protein)^*	6.6 (5.7–10.2)	12.8 (10.0–13.3)	0.032
bFGF (pg/μg protein)^*	5.0 (3.81–8.37)	7.3 (6.03–10.43)	0.29
PDGF-BB (pg/μg protein)^*	0.3 (0.3–0.6)	0.4 (0.4–0.7)	0.46
MCP-1 (pg/μg protein)^*	2.3 (1.5–3.0)	2.5 (1.8–2.8)	0.88
IGFBP-1 (pg/μg protein)^*	38.6 (23.6–72.3)	17.3 (14.2–23.1)	0.05

Data is presented as median (interquartile range). P values represent Mann–Whitney U tests.

Tissue for TGF-β1 quantification was available for 4 responders and 5 non-responders; for FGF 4 responders and 6 non-responders, for PDGF-BB, MCP-1 and IGFBP-1 included 3 responders and 5 nonresponders.